Corcept 制药

最新新闻

• Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• 评级变动
  H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $135
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)
  TipRanks · 2026/6/1
• Corcept Therapeutics(CORT.US) Officer Sells US$3.89 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• 评级变动
  UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $161
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $161
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $95
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• 评级变动
  Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Wolfe Research Downgrades Corcept Therapeutics(CORT.US) to Sell Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Wolfe Research Maintains Corcept Therapeutics(CORT.US) With Sell Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
  \u5e02\u573a\u8d44\u8baf · 2026/9/19
• Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
  \u5e02\u573a\u8d44\u8baf · 2026/8/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。